CA Healthcare Acquisition Corp.

CA Healthcare Acquisition Corp.

CAHCW
CA Healthcare Acquisition Corp.US flagNASDAQ Capital Market
1.31
USD
+0.08
- -
No data availableFinancial data will appear here once available

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Company Description

APIChatGPT
CEO
Larry J. Neiterman
Sector
Financial Services
Industry
Shell Companies
Address
99 Summer Street Boston MA United States of America
IPO Date
Mar 9, 2021
Business
CA Healthcare Acquisition Corp. (NASDAQ:CAHCW) operates as a blank check company whose sole purpose is to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities, with a focus on the healthcare industry including healthcare services; healthcare information technology; care management; behavioral health; medical devices; diagnostics; pharma services; health and wellness; and specialty pharmacy. Founded in 2020 and headquartered at 99 Summer Street, Suite 200, Boston, Massachusetts, the company went public via an initial public offering on March 9, 2021, raising $100 million, and its warrants (CAHCW) are exercisable into common shares expiring December 25, 2025. In September 2021, it completed a merger with LumiraDx Limited, a UK-based next-generation point-of-care diagnostics company, valuing LumiraDx at $3.0 billion enterprise value (excluding IPO proceeds); post-merger, LumiraDx common shares traded under LMDX and warrants under LMDXW on Nasdaq, while CAHCW warrants from the SPAC continue to trade separately with no reported further business combinations, funding rounds, acquisitions, or operational changes as of late 2025. The company maintains a small team of 2-10 employees and targets global healthcare opportunities without current significant operations beyond seeking such transactions.